Dr. Michael Kauffman is the cofounding CEO of Karyopharm Therapeutics.
He was the Chief Medical Officer of Onyx Pharmaceuticals Inc., where he was a key leader in the development of Kyprolis™ (carfilzomib), a novel proteasome inhibitor approved in refractory myeloma.